Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.63 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21616820 | 0.92 | TMEM97 (0.62) | SIGMAR1TMEM97NPC1 | |
| SCHEMBL21616834 | 0.92 | TMEM97 (0.62) | SIGMAR1TMEM97 | |
| SCHEMBL12124611 | 0.81 | SIGMAR1 (0.63) | SIGMAR1TMEM97KMT2A | |
| SCHEMBL12124517 | 0.79 | — | — | |
| SCHEMBL31757917 | 0.78 | TMEM97 (0.57) | SIGMAR1TMEM97KMT2A | |
| SCHEMBL31033181 | 0.78 | SIGMAR1 (1.00) | SIGMAR1TMEM97 | |
| Hydrochloric Acid SCHEMBL28948352 | 0.77 | NPC1 (0.59) | SIGMAR1NPC1ALDH1A1LMNAPKM | |
| SCHEMBL12124423 | 0.77 | SIGMAR1 (0.71) | SIGMAR1TMEM97ALDH1A1HPGD | |
| SCHEMBL6408326 | 0.76 | TMEM97 (0.72) | SIGMAR1TMEM97 | |
| SCHEMBL12061417 | 0.75 | NPC1 (0.64) | SIGMAR1NPC1ALDH1A1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230131-A1 | POLYAMINO BIARYL COMPOUNDS AND THEIR USE | CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU) (FR) | 2021-07-29 | — | — | US | disclosed |
| EP-3820862-A1 | POLYAMINO BIARYL COMPOUNDS AND THEIR USE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020011848-A1 | POLYAMINO BIARYL COMPOUNDS AND THEIR USE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020011848-A1 | POLYAMINO BIARYL COMPOUNDS AND THEIR USE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230131-A1 | POLYAMINO BIARYL COMPOUNDS AND THEIR USE | ABCG2, SLC10A1, CYP3A43 | SIGMAR1 148/4885TMEM97 1765/4885NPC1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.